The gap between audacious tech promises and the messy reality of execution has never been wider. From decoding the grunts of our pets to building nuclear-powered rockets, the allure of breakthrough technologies has kept researchers and investors chasing impossibilities for decades. But as MIT Technology Review’s new “Impossible Issue” makes clear, many of these moonshots remain stubbornly stuck just beyond the horizon. Meanwhile, the biotech world is confronting its own blind spots — a stark reminder, courtesy of the Theranos saga, that even the most compelling narratives can hide catastrophic failures. This convergence of tech ambition and biotech accountability forms a critical moment for anyone who follows science and innovation.
The Impossible Issue: Six Big Promises Under the Microscope
Some ideas are too tantalizing to abandon. Decoding a pet’s yowls and yips? Absolutely. Scrubbing the world of forever chemicals? Yes, please. Rocketing to Mars in a fraction of the time? Sounds great — but how close are we, really? MIT Technology Review’s latest special issue takes a hard look at six transformative technologies that have been “just around the corner” for years, even decades. From an exercise-in-a-pill to nuclear-powered spaceships, the publication asked experts what’s holding these concepts back and how far they’ve actually come.
The progress reports cover a spectrum of ambition. On one end, decoding animal communication has moved from fantasy to preliminary research, with machine learning models beginning to parse vocalizations in dogs and cats. On the other, nuclear thermal rockets for Mars travel remain largely confined to blueprints and small-scale testbeds. The common thread is that each technology faces fundamental scientific or engineering hurdles that no amount of hype can dissolve. The issue’s central question — “Are we there yet?” — gets a resounding “not quite” for all six, but with nuanced gradations of progress.
These are not failures; they are reality checks. And they matter because the gap between promise and delivery fuels skepticism that can damage even legitimate fields. The article series, which will be unpacked over the coming days in The Download newsletter, offers a template for how to assess emerging technologies without being seduced by their appeal.
Biotech’s Blind Spots: What the Theranos Documentary Exposes
If the Impossible Issue offers a forward-looking reality check, the recent film You Can See Everything serves as a backward-facing cautionary tale. The buzzy documentary about disgraced former Theranos CEO Elizabeth Holmes has reignited a troubling question for science journalists: How do we cover science when we can never actually see everything?
Jessica Hamzelou, a senior biotech reporter at MIT Technology Review, attended a screening of the film and came away unsettled — not just by Holmes’s fraud or the disturbing interactions between subjects, but by the film’s deeper implication. “Despite our best efforts, we never can actually see everything,” she writes. The documentary is a stark reminder of how easy it is to fall for an appealing narrative, especially when that narrative promises to revolutionize medicine.
Theranos was a company that claimed to run hundreds of diagnostic tests from a single drop of blood. The story was irresistible: a young, charismatic founder, a device that could democratize healthcare, and a valuation that soared into the billions. But behind the narrative lay a catastrophic failure of both technology and oversight. The film forces viewers to confront the uncomfortable reality that many in the media, including some at MIT Technology Review, initially bought into the hype. Hamzelou’s reflection on the documentary — published in the magazine’s weekly biotech newsletter The Checkup — is a must-read for anyone who reports on science or consumes it. It asks whether the systems in place to vet biotech claims are adequate, and whether journalistic skepticism is strong enough to pierce even the most polished narratives.
This Week’s Notable Developments in Tech and Biotech
While the Impossible Issue and the Theranos documentary provide the big-picture context, the past week brought a series of concrete developments that illustrate the themes of promise, peril, and progress.
Gene Editing Crosses a New Threshold
A powerful new gene editor, based on the prime editing technique, has reached its first human patient. The treatment rewrites DNA in liver cells, offering a potential cure for genetic diseases that have long resisted conventional approaches. This milestone, reported by Nature, represents a genuine advance in the biotech pipeline — but it also comes with its own set of unknowns, including off-target effects and long-term safety. The same day, news emerged that companies are planning gene-edited babies, reigniting the ethical debates that have shadowed CRISPR since its inception.
mRNA Cancer Vaccine Shows Promising Results
Moderna and Merck announced that their personalized mRNA cancer vaccine reduced the risk of melanoma recurrence and death by 42%. The results, published by Ars Technica, mark a significant step for mRNA technology beyond COVID-19. Yet, as MIT Technology Review has previously reported, federal health agencies in the United States are abandoning mRNA vaccines amid shifting political and regulatory winds — a reminder that technological breakthroughs can be undermined by non-scientific factors.
The PHP Vulnerability That Almost Broke the Internet
Not all tech news is about glamorous breakthroughs. A newly disclosed PHP flaw sent administrators scrambling to patch servers worldwide. As of yet, no successful attacks have been reported, but experts told NBC News that the vulnerabilities are harder to exploit than initially feared. Still, the incident highlighted the fragility of the internet’s infrastructure — and the unsung heroes who keep it running. Software developer Ian Landsman posted on X that volunteer Ondřej Surý’s work on patching PHP makes him an unsung hero: “If anything happens to this guy, that’s just it. Everyone is screwed.” It’s a sobering reminder that innovation often depends on the quiet labor of individuals who never make the headlines.
Palmer Luckey’s New Startup: Genetically Enhanced Military Dogs
Oculus founder Palmer Luckey has a new venture: Warhound, a startup that plans to genetically enhance military dogs to detect explosives and protect troops. The company has already raised $200 million from investors including Sequoia, and is partnering with Colossal Biosciences to clone and gene-edit the animals. The Pentagon, meanwhile, is also pursuing an AI-powered lie detector. This intersection of biotechnology and military applications raises ethical questions that echo those of the Theranos era — can we trust the promises of a charismatic founder when the stakes are life and death?
Listening to the Universe: Sonification Opens a New Window
Amid the hype and caution, there is also quiet innovation worth celebrating. For decades, astronomy has relied on visual data — images, charts, graphs. Now, some researchers are doing something different: they are listening to the universe. Using sonification, the process of turning data into sound, scientists are helping blind and visually impaired researchers explore the cosmos. More surprisingly, sonification is revealing patterns in astronomical data that might otherwise go unnoticed. The approach is spreading into climate science, navigation, and education. It’s a reminder that progress doesn’t always come in the form of a breakthrough pill or a rocket engine — sometimes it’s about finding new ways to perceive what’s already there.
The work, detailed by Corey S. Powell in MIT Technology Review, shows that the most promising technologies are often those that broaden access and perspective. By making science more inclusive, sonification may also make it more rigorous.
Where the Real Work Happens
The Impossible Issue and the Theranos documentary serve opposite but complementary functions. One asks us to look forward with tempered optimism; the other forces us to look backward with humility. Together, they define the narrow path that any credible tech or biotech coverage must walk: embrace the transformative potential of science, but never lose sight of the blind spots.
The most honest answer to “Are we there yet?” is that we are always somewhere in between — between the lab and the clinic, between the prototype and the product, between the narrative and the evidence. The real work lies in staying in that uncomfortable middle ground, reporting on progress without hyping it, and covering failures without letting them sour us on genuine innovation.
